Tetra Bio Pharma Inc (TBP.CA) Stock Price, Forecast & Analysis
Canada - Toronto Stock Exchange - TSX:TBP - CA88166Y1007 - Common Stock
TBP.CA Key Statistics, Chart & Performance
The current stock price of TBP.CA is 0.025 CAD. In the past year, price decreased by -64.29%.
TBP.CA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| BHC.CA | BAUSCH HEALTH COS INC | 1.87 | 3.63B | ||
| TLRY.CA | TILRAY BRANDS INC | N/A | 1.48B | ||
| CRON.CA | CRONOS GROUP INC | 24.27 | 1.39B | ||
| DHT-UN.CA | DRI HEALTHCARE TRUST | 7.04 | 873.49M | ||
| WEED.CA | CANOPY GROWTH CORP | N/A | 607.96M | ||
| GUD.CA | KNIGHT THERAPEUTICS INC | N/A | 595.74M | ||
| NGEN.CA | NERVGEN PHARMA CORP | N/A | 514.92M | ||
| CPH.CA | CIPHER PHARMACEUTICALS INC | 16.63 | 379.79M | ||
| TSND.CA | TERRASCEND CORP | N/A | 357.20M | ||
| ACB.CA | AURORA CANNABIS INC | N/A | 331.70M | ||
| HITI.CA | HIGH TIDE INC | N/A | 322.82M | ||
| OGI.CA | ORGANIGRAM GLOBAL INC | N/A | 311.65M |
Related stock screener links
About TBP.CA
Company Profile
Tetra Bio-Pharma, Inc. engages in the discovery and development of cannabinoid-based drugs and treatments. The company is headquartered in Orleans, Ontario and currently employs 33 full-time employees. The company went IPO on 2008-04-15. The firm has developed a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology. The firm has a pipeline of formulations and drug delivery systems with a portfolio of assets in early research and development phase to advanced stage clinical programs. Its products include QIXLEEF, CAUMZ, PPP004, REDUVO, and REBORN 1. QIXLEEF is a botanical therapy with a fixed dosage of tetrahydrocannabinol (THC) and cannabidiol (CBD). CAUMZ is its inhaled cannabinoid-derived drug candidate. PPP004 is a topical preparation containing either a standardized amount of CBD or a defined ratio of THC and CBD. REDUVO is a soft gel capsule used to treat chemotherapy-induced nausea and vomiting (CINV) and weight loss and severe nausea in people living with human immunodeficiency virus (HIV) infection. REBORN 1 is in phase II study.
Company Info
Tetra Bio Pharma Inc
2316 St-Joseph Blvd.
ORLEANS ONTARIO K1C 1E8 CA
CEO: Richard Giguere
Employees: 33
Phone: 13436890714.0
Tetra Bio Pharma Inc / TBP.CA FAQ
What does TBP do?
Tetra Bio-Pharma, Inc. engages in the discovery and development of cannabinoid-based drugs and treatments. The company is headquartered in Orleans, Ontario and currently employs 33 full-time employees. The company went IPO on 2008-04-15. The firm has developed a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology. The firm has a pipeline of formulations and drug delivery systems with a portfolio of assets in early research and development phase to advanced stage clinical programs. Its products include QIXLEEF, CAUMZ, PPP004, REDUVO, and REBORN 1. QIXLEEF is a botanical therapy with a fixed dosage of tetrahydrocannabinol (THC) and cannabidiol (CBD). CAUMZ is its inhaled cannabinoid-derived drug candidate. PPP004 is a topical preparation containing either a standardized amount of CBD or a defined ratio of THC and CBD. REDUVO is a soft gel capsule used to treat chemotherapy-induced nausea and vomiting (CINV) and weight loss and severe nausea in people living with human immunodeficiency virus (HIV) infection. REBORN 1 is in phase II study.
Can you provide the latest stock price for Tetra Bio Pharma Inc?
The current stock price of TBP.CA is 0.025 CAD.
What is the dividend status of Tetra Bio Pharma Inc?
TBP.CA does not pay a dividend.
How is the ChartMill rating for Tetra Bio Pharma Inc?
TBP.CA has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What sector and industry does Tetra Bio Pharma Inc belong to?
Tetra Bio Pharma Inc (TBP.CA) operates in the Health Care sector and the Pharmaceuticals industry.
Should I buy TBP stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on TBP.CA.
TBP.CA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to TBP.CA. When comparing the yearly performance of all stocks, TBP.CA is a bad performer in the overall market: 86.45% of all stocks are doing better.
TBP.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to TBP.CA. Both the profitability and financial health of TBP.CA have multiple concerns.
TBP.CA Financial Highlights
Over the last trailing twelve months TBP.CA reported a non-GAAP Earnings per Share(EPS) of -0.09. The EPS increased by 7.3% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |